X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (167) 167
oncology (133) 133
female (116) 116
male (111) 111
middle aged (111) 111
adult (104) 104
index medicus (100) 100
aged (91) 91
hematology (88) 88
chemotherapy (58) 58
antineoplastic combined chemotherapy protocols - therapeutic use (57) 57
lymphomas (55) 55
cancer (54) 54
treatment outcome (50) 50
prognosis (48) 48
lymphoma (44) 44
aged, 80 and over (39) 39
therapy (34) 34
care and treatment (31) 31
non-hodgkins-lymphoma (30) 30
adolescent (29) 29
mantle cell lymphoma (27) 27
patients (26) 26
transplantation (25) 25
expression (23) 23
recurrence (23) 23
survival (23) 23
[ sdv.can ] life sciences [q-bio]/cancer (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
antineoplastic agents - therapeutic use (20) 20
disease-free survival (20) 20
hematology, oncology and palliative medicine (19) 19
young adult (19) 19
[sdv.can]life sciences [q-bio]/cancer (18) 18
life sciences (18) 18
radiotherapy (18) 18
rituximab (18) 18
survival rate (18) 18
clinical trials (17) 17
cytarabine - administration & dosage (17) 17
prospective studies (17) 17
tumors (16) 16
analysis (15) 15
antineoplastic agents - adverse effects (15) 15
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
lymphoma, non-hodgkin - drug therapy (15) 15
b-cell lymphoma (14) 14
doxorubicin - therapeutic use (14) 14
drug therapy (14) 14
medical research (14) 14
remission induction (14) 14
retrospective studies (14) 14
survival analysis (14) 14
antineoplastic agents (13) 13
combined modality therapy (13) 13
cyclophosphamide - administration & dosage (13) 13
cyclophosphamide - therapeutic use (13) 13
disease (13) 13
dose-response relationship, drug (13) 13
drug administration schedule (13) 13
hemic and lymphatic diseases (13) 13
lymphoma, mantle-cell - drug therapy (13) 13
prednisone - therapeutic use (13) 13
risk factors (13) 13
trial (13) 13
vincristine - therapeutic use (13) 13
abridged index medicus (12) 12
gene expression (12) 12
high-dose therapy (12) 12
hodgkin disease - drug therapy (12) 12
lymphocytes b (12) 12
lymphoma, mantle-cell - therapy (12) 12
mutation (12) 12
neoplasm staging (12) 12
pharmacology & pharmacy (12) 12
radiology, nuclear medicine & medical imaging (12) 12
toxicity (12) 12
animals (11) 11
follow-up studies (11) 11
hodgkin lymphoma (11) 11
immunotherapy (11) 11
leukemia (11) 11
lymphoma, mantle-cell - genetics (11) 11
medicine, general & internal (11) 11
relapse (11) 11
research (11) 11
antimitotic agents (10) 10
chronic lymphocytic-leukemia (10) 10
cyclophosphamide (10) 10
disease progression (10) 10
doxorubicin - administration & dosage (10) 10
drug resistance, neoplasm (10) 10
etoposide - administration & dosage (10) 10
immunochemotherapy (10) 10
immunology (10) 10
lymphoma, mantle-cell - pathology (10) 10
medicine & public health (10) 10
neoplasms - drug therapy (10) 10
non-hodgkin-lymphoma (10) 10
nuclear reactions (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 7, pp. 1409 - 1411
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMBINATION | FLUDARABINE | STUDY-GROUP GLSG | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2017, Volume 35, Issue S2, pp. 279 - 280
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2013, Volume 24, Issue suppl 1, pp. i13 - i13
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2017, Volume 35, Issue S2, pp. 392 - 392
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2017, Volume 28, Issue suppl_5
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
Journal Article
Gene, ISSN 0378-1119, 04/2016, Volume 580, Issue 2, pp. 134 - 143
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 01/2018, Volume 59, Issue 1, pp. 15 - 24
The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for the assessment of chemotherapy and targeted molecular agents. We... 
FDG-PET/CT | CRITERIA | PROVIDE | SOLID TUMORS | GUIDELINES | Cheson | POSITRON-EMISSION-TOMOGRAPHY | THERAPY | Lugano | CLINICAL BENEFIT | RADIOTHERAPY | BLOCKADE | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Hodgkin lymphoma | immunomodulatory
Journal Article
Haematologica, ISSN 0390-6078, 02/2016, Volume 101, Issue 2, pp. 115 - 208
Journal Article